Source: Annual Congress 2002 - Regulation of responsiveness and inflammation in airway disease
Disease area: Airway diseases

Abstract

Aim of this study was to evaluate if the administration of ipratropium bromide(IB) before or after methacholine challenge test (Mch-t) could influence PD20FEV1 and the following recovery phase. Sixteen asthmatics (M:9;F:7; mean age:26.3; prick tests positive:14) were enrolled; all of them had PD20FEV1 <200 mcg. Pts randomly underwent three Mch-t(cumulative dose method). Of them, two foresaw the administration of IB(40mcg) the one before Mch-t (pre-IB) and the other after PD20FEV1(post-IB); the third test was the control (SR). For each test we registered PD20FEV1 and cumulative dose (CD); FEV1 was performed before the test, at PD20 and 60 minutes after PD20FEV1.In pre-IB results showed it was necessary to administer an amount of Mch 8 times higher(*= p<.01) than in control and in post-IB test(table 1).Sixty minutes after PD20FEV1 an incomplete recovery was found in control(^=p<.05) and in pre-IB;a complete recovery was found in post-IB.If the recovery was analysed in relation with the Mch CD this phase was more efficient (linear regression: p<.001)in the test pre-administered with IB. Drug confirmed to have a good bronchodilator and protective activity against Mch induced bronchospasm but the pre-administration of IB showed also an effect on the recovery phase.

	SR	pre-IB	post-IB
FEV1% baseline	100.4(12.1)	98.4(8.9)	98.7(10.4)
FEV1% after PD20	75.2(4.4)	77.4(2.8)	75.7(3.04)
FEV1 % at T60	94.1(5.5)^	97.1(8.3)	101(6.2)
PD20FEV1 (mcg)	73.9(41.8)	695(587.6)*	89.7(70.9)
Cumulative dose (mcg)	103.1(63.8)	795.3(681.7)*	117.9(94.2)

Rating:

Share or cite this content

Citations should be made in the following way:
F. Mannino, B. Sposato, A. Ricci, G. Failla, S. Mariotta (Rome, Italy). Ipratropium bromide pre-treatment influences recovery after methacholine induced bronchospasm. Eur Respir J 2002; 20: Suppl. 38, 3153

Member's Comments

No comment yet.

Related content which might interest you: Acute reversal of allergen-induced airway hyperresponsiveness (AHR) by olodaterol is synergistically enhanced by tiotropium bromide Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011 Cardiopulmonary effects of inhaled ipratropium bromide and its combination with fenoterol in patients with bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 58s Year: 2002 Effect of patient age on response to nebulised salbutamol or ipratropium bromide Source: Annual Congress 2012 - Going with the flow: assessment and evaluation of airway function and its role in patient management Year: 2012 A comparison of early bronchodilating responses of Salbutamol, Ipratropium bromide, and the combination of Ipratropium bromide-Salbutamol in stable patients with COPD or asthma Source: Eur Respir J 2002; 20: Suppl. 38, 246s Year: 2002 Reversibility effects of ipratropium bromide and terbutalin sulphate in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 72s Year: 2001 Comparison of nebulized ipratropium bromide with salbutamol versus salbutamol alone in acute asthma exacerbation in children Source: Eur Respir J 2004; 24: Suppl. 48, 167s Year: 2004 How long should tiotropium bromide be suspended before methacholine challenge? Source: Eur Respir J 2006; 28: Suppl. 50, 218s Year: 2006 Influence of tiotropium bromide and formoterol on bronchial hyperresponsiveness in COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 Assessments of protective effects of tiotropium bromide against methacholine- and neurokinin A-induced bronchoconstriction in patients with asthma Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Six months treatment with salmeterol or ipratropium bromide improves effort tolerance and reduces dyspnoea but does not have any effect on lung function in COPD Source: Eur Respir J 2002; 20: Suppl. 38, 108s Year: 2002 Airway tone during exercise in healthy subjects: effects of salbutamol and ipratropium bromide Source: Eur Respir J 2003; 22: Suppl. 45, 89s Year: 2003 Pulmonary function and bronchodilator response to albuterol, ipratropium bromide and association of albuterol and ipratropium bromide in children with cystic fibrosis (CF) Source: Eur Respir J 2003; 22: Suppl. 45, 229s Year: 2003 Changes in the lung metabolic functions by inhalation of ipratropium bromide Source: International Congress 2019 – Exploring the lungs in various pathophysiological conditions Year: 2019 The impact of tiotropium for exercise induced bronchoconstriction Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 Long-acting anticholinergic, aclidinium bromide (AB) significantly attenuates airway inflammation and hyper-responsiveness in an AF-induced murine model of asthma Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009 Comparative study of the effects of tiotropium bromide and budesonide on allergen-induced airway remodeling Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006 Protection by formoterol and salmeterol on bronchoconstriction provoked by methacholine and AMP in asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 307s Year: 2002 Influence of higher than conventional doses of salbutamol or ipratropium bromide on bronchodilation induced by a regular treatment with tiotropium in patients suffering from stable COPD Source: Eur Respir J 2007; 30: Suppl. 51, 356s Year: 2007 NVA237 has similar efficacy as tiotropium bromide against methacholine-induced bronchoconstriction and less systemic effect on cardiovascular variables in an anaesthetized rabbit model Source: Eur Respir J 2006; 28: Suppl. 50, 436s Year: 2006 Evaluation of bronchodilator response to single dose tiotropium bromide Source: Eur Respir J 2004; 24: Suppl. 48, 504s Year: 2004